The history of the erectile dysfunction drug presents a intricate picture for investors. While the initial launch generated significant gains, the lapse of its exclusive rights opened the floodgates to off-brand https://tvsocialnews.com/story7268301/the-copyright-and-pharma-a-risky-opportunity